Genasense

A substance that is being studied in the treatment of cancer. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs. It belongs to the family of drugs called antisense oligodeoxyribonucleotides. Also called oblimersen, augmerosen, and bcl-2 antisense oligodeoxynucleotide G3139.

English dictionary of cancer terms . 2015.

Look at other dictionaries:

  • Oblimersen — Clinical data Pregnancy cat.  ? Legal status  ? Identifiers ATC code L01 …   Wikipedia

  • Bcl-2 — is the prototype for a family of mammalian genes and the proteins they produce. They govern mitochondrial outer membrane permeabilization (MOMP) and can be either pro apoptotic (Bax, BAD, Bak and Bok among others) or anti apoptotic (including Bcl …   Wikipedia

  • Colorectal cancer — Classification and external resources Diagram of the lower gastrointestinal tract ICD 10 C …   Wikipedia

  • augmerosen — A substance that is being studied in the treatment of cancer. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs. It belongs to the family of… …   English dictionary of cancer terms

  • bcl-2 antisense oligodeoxynucleotide G3139 — A substance that is being studied in the treatment of cancer. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs. It belongs to the family of… …   English dictionary of cancer terms

  • oblimersen — A substance that is being studied in the treatment of cancer. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs. It belongs to the family of… …   English dictionary of cancer terms

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.